{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:17:47Z","timestamp":1788286667523,"version":"build-2803163510"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To report the first and largest systematic review and meta-analysis of randomized controlled trials (RCT) to evaluate the efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression (TRD) or major depressive disorder(MDD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic literature retrieval via PubMed, Embase, Web of Science, and Cochrane until April 2023 for RCT, which evaluated the efficacy and safety of aripiprazole or bupropion augmentation and switching for patients with TRD or MDD. Outcomes measured were changes in the Montgomery-Asberg Depression Rating Scale (MADRS), response and remission rate, and serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five RCTs, including 4480 patients, were included for meta-analysis. Among them, two RCTs were rated as \"high risk\" in three aspects (allocation concealment, blinding of participants and personnel and blinding of outcome assessment) because of the non-blind method, and the quality evaluation of the remaining works of literature was \"low risk\". Augmentation treatment with Aripiprazole (A-ARI) was associated with a significant higher response rate compared with augmentation treatment with bupropion (A-BUP) (RR: 1.15; 95% CI: 1.05, 1.25; P = 0.0007; I2 = 23%). Besides, A-ARI had a significant higher remission rate compared with switching to bupropion (S-BUP) (RR: 1.22; 95% CI: 1.00, 1.49; P = 0.05; I2 = 59%) and A-BUP had a significant higher remission rate compared with S-BUP (RR: 1.20; 95% CI: 1.06, 1.36; P = 0.0004; I2 = 0%). In addition, there was no significant difference in remission rate(RR: 1.05; 95% CI: 0.94, 1.17; P = 0.42; I2 = 33%), improvement of MADRS(WMD: -2.07; 95% CI: -5.84, 1.70; P = 0.28; I2 = 70%) between A-ARI and A-BUP. No significant difference was observed in adverse events and serious adverse events among the three treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A-ARI may be a better comprehensive antidepressant treatment strategy than A-BUP or S-BUP for patients with TRD or MDD. More large-scale, multi-center, double-blind RCTs are needed to further evaluated the efficacy and safety of aripiprazole or bupropion augmentation and switching treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0299020","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T13:26:20Z","timestamp":1714137980000},"page":"e0299020","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["RETRACTED: Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1371","volume":"19","author":[{"given":"Mengjia","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1346-1164","authenticated-orcid":true,"given":"Guirong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"issue":"4","key":"pone.0299020.ref001","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/jgs.17592","article-title":"\"What else can we do?\"-Provider perspectives on treatment-resistant depression in late life","volume":"70","author":"ME Hamm","year":"2022","journal-title":"J Am Geriatr Soc"},{"issue":"13","key":"pone.0299020.ref002","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1056\/NEJMp1311047","article-title":"Diagnosing depression in older adults in primary care","volume":"370","author":"R. Mojtabai","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"11","key":"pone.0299020.ref003","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.euroneuro.2007.03.009","article-title":"What is the meaning of treatment resistant\/refractory major depression (TRD)? A systematic review of current randomized trials","volume":"17","author":"MT Berlim","year":"2007","journal-title":"European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology"},{"issue":"5","key":"pone.0299020.ref004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1192\/bjp.bp.112.118307","article-title":"Late-life depression and risk of vascular dementia and Alzheimer\u2019s disease: systematic review and meta-analysis of community-based cohort studies","volume":"202","author":"BS Diniz","year":"2013","journal-title":"The British journal of psychiatry: the journal of mental science"},{"issue":"6","key":"pone.0299020.ref005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrneurol.2011.60","article-title":"Depression and risk of developing dementia","volume":"7","author":"AL Byers","year":"2011","journal-title":"Nature reviews Neurology"},{"issue":"5","key":"pone.0299020.ref006","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.63.5.530","article-title":"Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis","volume":"63","author":"RL Ownby","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"pone.0299020.ref007","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1034\/j.1600-0447.2002.10078.x","article-title":"The impact of depression on the well-being, disability and use of services in older adults: a longitudinal perspective","volume":"105","author":"AT Beekman","year":"2002","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"pone.0299020.ref008","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00019442-200105000-00004","article-title":"The association of late-life depression and anxiety with physical disability: a review of the literature and prospectus for future research","volume":"9","author":"EJ Lenze","year":"2001","journal-title":"The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry"},{"issue":"11","key":"pone.0299020.ref009","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4088\/JCP.v63n1102","article-title":"The impact of treatment-resistant depression on health care utilization and costs","volume":"63","author":"WH Crown","year":"2002","journal-title":"The Journal of clinical psychiatry"},{"issue":"12","key":"pone.0299020.ref010","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa2204462","article-title":"Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression","volume":"388","author":"EJ Lenze","year":"2023","journal-title":"The New England journal of medicine"},{"issue":"10011","key":"pone.0299020.ref011","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(15)00308-6","article-title":"Efficacy, safety, and tolerability of augmentation pharmacotherapy with Aripiprazole for treatment-resistant depression in late life: a randomized, double-blind, placebo-controlled trial","volume":"386","author":"EJ Lenze","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"2","key":"pone.0299020.ref012","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jama.2017.8036","article-title":"Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial","volume":"318","author":"S Mohamed","year":"2017","journal-title":"Jama"},{"issue":"2","key":"pone.0299020.ref013","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/JCP.0000000000000663","article-title":"Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study","volume":"37","author":"EJ Cheon","year":"2017","journal-title":"Journal of clinical psychopharmacology"},{"key":"pone.0299020.ref014","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ (Clinical research ed)"},{"key":"pone.0299020.ref015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"X Wan","year":"2014","journal-title":"BMC medical research methodology"},{"issue":"6","key":"pone.0299020.ref016","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"D Luo","year":"2018","journal-title":"Statistical methods in medical research"},{"key":"pone.0299020.ref017","first-page":"Ed000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"M Cumpston","year":"2019","journal-title":"The Cochrane database of systematic reviews"},{"issue":"11","key":"pone.0299020.ref018","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"JP Higgins","year":"2002","journal-title":"Statistics in medicine"},{"issue":"1","key":"pone.0299020.ref019","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12294","article-title":"Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other \"Next-Step\" Depression Treatment Strategies: A Randomized Clinical Trial","volume":"80","author":"J Yoon","year":"2018","journal-title":"The Journal of clinical psychiatry"},{"issue":"2","key":"pone.0299020.ref020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/da.23114","article-title":"Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST-D report","volume":"38","author":"S Zisook","year":"2021","journal-title":"Depression and anxiety"},{"key":"pone.0299020.ref021","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jad.2016.12.013","article-title":"The effect of treatment as usual on major depressive disorder: A meta-analysis","volume":"210","author":"S Kolovos","year":"2017","journal-title":"Journal of affective disorders"},{"issue":"5","key":"pone.0299020.ref022","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines","volume":"29","author":"A Cleare","year":"2015","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"issue":"9","key":"pone.0299020.ref023","first-page":"540","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3","volume":"61","author":"SH Kennedy","year":"2016","journal-title":"Pharmacological Treatments. Canadian journal of psychiatry Revue canadienne de psychiatrie"},{"issue":"8","key":"pone.0299020.ref024","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/da.22378","article-title":"THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS\u2019 PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS","volume":"32","author":"JF Goldberg","year":"2015","journal-title":"Depression and anxiety"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0357331","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:55:08Z","timestamp":1788285308000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299020"}},"subtitle":[],"editor":[{"given":"Sairah","family":"Hafeez Kamran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0299020","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]}}}